These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16281071)

  • 61. Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.
    Buonamici S; Ottaviani E; Testoni N; Montefusco V; Visani G; Bonifazi F; Amabile M; Terragna C; Ruggeri D; Piccaluga PP; Isidori A; Malagola M; Baccarani M; Tura S; Martinelli G
    Blood; 2002 Jan; 99(2):443-9. PubMed ID: 11781223
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
    Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
    Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia.
    Freireich EJ; Cork A; Stass SA; McCredie KB; Keating MJ; Estey EH; Kantarjian HM; Trujillo JM
    Leukemia; 1992 Jun; 6(6):500-6. PubMed ID: 1602788
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
    van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
    Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
    Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
    Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience.
    Guièze R; Renneville A; Cayuela JM; Abdelali RB; Boissel N; de Botton S; Rubio MT; Mazingue F; Macintyre EA; Cheok M; Sigaux F; Fenaux P; Dombret H; Preudhomme C
    Leukemia; 2010 Jul; 24(7):1386-8. PubMed ID: 20508610
    [No Abstract]   [Full Text] [Related]  

  • 67. Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia.
    Rowe D; Cotterill SJ; Ross FM; Bunyan DJ; Vickers SJ; Bryon J; McMullan DJ; Griffiths MJ; Reilly JT; Vandenberghe EA; Wilson G; Watmore AE; Bown NP
    Br J Haematol; 2000 Dec; 111(4):1051-6. PubMed ID: 11167739
    [TBL] [Abstract][Full Text] [Related]  

  • 68. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
    Iriyama N; Hatta Y; Takeuchi J; Ogawa Y; Ohtake S; Sakura T; Mitani K; Ishida F; Takahashi M; Maeda T; Izumi T; Sakamaki H; Miyawaki S; Honda S; Miyazaki Y; Taki T; Taniwaki M; Naoe T
    Leuk Res; 2013 Sep; 37(9):1021-6. PubMed ID: 23810283
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A novel RT-qPCR assay for quantification of the MLL-MLLT3 fusion transcript in acute myeloid leukaemia.
    Abildgaard L; Ommen HB; Lausen B; Hasle H; Nyvold CG
    Eur J Haematol; 2013 Nov; 91(5):394-8. PubMed ID: 23772754
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.
    Gorello P; Cazzaniga G; Alberti F; Dell'Oro MG; Gottardi E; Specchia G; Roti G; Rosati R; Martelli MF; Diverio D; Lo Coco F; Biondi A; Saglio G; Mecucci C; Falini B
    Leukemia; 2006 Jun; 20(6):1103-8. PubMed ID: 16541144
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.
    Venditti A; Buccisano F; Del Poeta G; Maurillo L; Tamburini A; Cox C; Battaglia A; Catalano G; Del Moro B; Cudillo L; Postorino M; Masi M; Amadori S
    Blood; 2000 Dec; 96(12):3948-52. PubMed ID: 11090082
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
    Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 74. Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
    Attarbaschi A; Panzer-Grümayer R; Mann G; Möricke A; König M; Mecklenbräuker A; Teigler-Schlegel A; Bradtke J; Harbott J; Göhring G; Stanulla M; Schrappe M; Zimmermann M; Haas OA;
    Klin Padiatr; 2014 Nov; 226(6-7):338-43. PubMed ID: 25431866
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML.
    Nomdedéu JF; Hoyos M; Carricondo M; Bussaglia E; Estivill C; Esteve J; Tormo M; Duarte R; Salamero O; de Llano MP; García A; Bargay J; Heras I; Martí-Tutusaus JM; Llorente A; Ribera JM; Gallardo D; Aventin A; Brunet S; Sierra J;
    Leukemia; 2013 Nov; 27(11):2157-64. PubMed ID: 23584566
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion.
    van der Reijden BA; Simons A; Luiten E; van der Poel SC; Hogenbirk PE; Tönnissen E; Valk PJ; Löwenberg B; De Greef GE; Breuning MH; Jansen JH
    Br J Haematol; 2002 Aug; 118(2):411-8. PubMed ID: 12139724
    [TBL] [Abstract][Full Text] [Related]  

  • 77. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
    Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
    Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
    [TBL] [Abstract][Full Text] [Related]  

  • 78. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications.
    Schmidt HH; Strehl S; Thaler D; Strunk D; Sill H; Linkesch W; Jäger U; Sperr W; Greinix HT; König M; Emberger W; Haas OA
    Leukemia; 2004 Jun; 18(6):1115-21. PubMed ID: 15085163
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?
    Marcucci G; Caligiuri MA; Bloomfield CD
    Eur J Haematol; 2003 Sep; 71(3):143-54. PubMed ID: 12930314
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.